Mutations in the NF-kappaB signaling pathway: implications for human disease
- PMID: 17072331
- DOI: 10.1038/sj.onc.1209939
Mutations in the NF-kappaB signaling pathway: implications for human disease
Abstract
The nuclear factor-kappa B (NF-kappaB) signaling pathway is a multi-component pathway that regulates the expression of hundreds of genes that are involved in diverse and key cellular and organismal processes, including cell proliferation, cell survival, the cellular stress response, innate immunity and inflammation. Not surprisingly, mis-regulation of the NF-kappaB pathway, either by mutation or epigenetic mechanisms, is involved in many human and animal diseases, especially ones associated with chronic inflammation, immunodeficiency or cancer. This review describes human diseases in which mutations in the components of the core NF-kappaB signaling pathway have been implicated and discusses the molecular mechanisms by which these alterations in NF-kappaB signaling are likely to contribute to the disease pathology. These mutations can be germline or somatic and include gene amplification (e.g., REL), point mutations and deletions (REL, NFKB2, IKBA, CYLD, NEMO) and chromosomal translocations (BCL-3). In addition, human genetic diseases are briefly described wherein mutations affect protein modifiers or transducers of NF-kappaB signaling or disrupt NF-kappaB-binding sites in promoters/enhancers.
Similar articles
-
NF-kappaB-related genetic diseases.Cell Death Differ. 2006 May;13(5):843-51. doi: 10.1038/sj.cdd.4401841. Cell Death Differ. 2006. PMID: 16397577 Review.
-
NF-kappaB and inflammation in genetic disease.Biochem Pharmacol. 2006 Oct 30;72(9):1153-60. doi: 10.1016/j.bcp.2006.08.006. Epub 2006 Sep 11. Biochem Pharmacol. 2006. PMID: 16965764 Review.
-
NF-kappaB signaling pathway and its therapeutic implications in human diseases.Int Rev Immunol. 2008;27(5):293-319. doi: 10.1080/08830180802276179. Int Rev Immunol. 2008. PMID: 18853341 Review.
-
Analysis of the TLR/NF-kappaB pathway in antigen-presenting cells in malignancies promoted by inflammation.Methods Mol Biol. 2009;512:99-117. doi: 10.1007/978-1-60327-530-9_7. Methods Mol Biol. 2009. PMID: 19347275
-
Inhibitors of NF-kappaB signaling: 785 and counting.Oncogene. 2006 Oct 30;25(51):6887-99. doi: 10.1038/sj.onc.1209982. Oncogene. 2006. PMID: 17072334 Review.
Cited by
-
Cytokine-Targeted Therapeutics for KSHV-Associated Disease.Viruses. 2020 Sep 28;12(10):1097. doi: 10.3390/v12101097. Viruses. 2020. PMID: 32998419 Free PMC article. Review.
-
NF-κB2 mutation targets survival, proliferation and differentiation pathways in the pathogenesis of plasma cell tumors.BMC Cancer. 2012 May 29;12:203. doi: 10.1186/1471-2407-12-203. BMC Cancer. 2012. PMID: 22642622 Free PMC article.
-
Cartography of Pathway Signal Perturbations Identifies Distinct Molecular Pathomechanisms in Malignant and Chronic Lung Diseases.Front Genet. 2016 May 6;7:79. doi: 10.3389/fgene.2016.00079. eCollection 2016. Front Genet. 2016. PMID: 27200087 Free PMC article.
-
PIR promotes tumorigenesis of breast cancer by upregulating cell cycle activator E2F1.Cell Cycle. 2019 Nov;18(21):2914-2927. doi: 10.1080/15384101.2019.1662259. Epub 2019 Sep 10. Cell Cycle. 2019. PMID: 31500513 Free PMC article.
-
The Prp19 complex and the Usp4Sart3 deubiquitinating enzyme control reversible ubiquitination at the spliceosome.Genes Dev. 2010 Jul 1;24(13):1434-47. doi: 10.1101/gad.1925010. Genes Dev. 2010. PMID: 20595234 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous